Acutaas margin drops 12.61 points sequentially as stock falls 5.99%
Year-on-year growth remained strong, but revenue fell faster than expenses sequentially, reversing four quarters of margin expansion.
Filed 24 Jul 2026, 12:32 IST · Acutaas Chemicals Ltd (ACUTAAS)
Key takeaways
- Consolidated revenue grew +59.08% YoY and operating margin expanded 5.94 percentage points to 23.12%.
- Sequentially, revenue fell -23.82% while expenses declined only -8.87%, driving a 12.61 percentage-point margin contraction.
- The stock fell -5.99%, reversing a history of seven rises in eight post-results sessions and exceeding the 4.56% median absolute move.
Price around the results
YoY growth masks a sharp sequential reset
Acutaas reported consolidated revenue growth of +59.08% YoY, while operating profit rose +114.10% and net profit increased +70.39%. The sequential picture was weaker: revenue fell -23.82% and net profit declined -44.15% from Q4FY26. This marks a clear loss of momentum after the preceding quarter's revenue peak of Rs 432.75 cr.
Costs drove the 12.61-point margin contraction
Sequential expenses fell only -8.87% against the -23.82% revenue decline, so operating margin narrowed by 12.61 percentage points to 23.12%. YoY, revenue grew faster than expenses, producing a 5.94 percentage-point margin expansion. Other income contributed just 1.73% of pre-tax profit after falling -88.71% YoY and -83.80% sequentially, while the tax rate rose 3.61 percentage points YoY to 27.83%, limiting the flow-through to net profit.
Margin reversed after climbing through FY26
Operating margin rose from 17.18% in Q1FY26 to 35.73% in Q4FY26 before dropping to 23.12% this quarter. Acutaas was 1.52 percentage points below the 24.64% median operating margin of the eight Healthcare peers that had reported, placing it third from the bottom.
Results-day fall breaks the usual reaction pattern
The stock fell -5.99% on the results date, with a 3.06x volume ratio and a relative return of -5.56%. That was an unusual reversal for the stock, which had risen after seven of its last eight results; the decline was also larger than its 4.56% median absolute post-results move.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹330 cr | ₹433 cr | -23.82% | +59.08% |
| Other income | ₹2 cr | ₹11 cr | -83.80% | -88.71% |
| Expenses | ₹253 cr | ₹278 cr | -8.87% | +47.67% |
| Operating profit | ₹76 cr | ₹155 cr | -50.70% | +114.10% |
| Operating margin (%) | 23.12% | 35.73% | — | — |
| Interest | ₹1 cr | ₹1 cr | -4.20% | +78.12% |
| Depreciation | ₹10 cr | ₹10 cr | +1.97% | +20.79% |
| Profit before tax | ₹104 cr | ₹184 cr | -43.47% | +78.91% |
| Tax | ₹29 cr | ₹50 cr | -41.60% | +105.54% |
| Net profit | ₹75 cr | ₹134 cr | -44.15% | +70.39% |
| EPS (₹) | ₹9.07 | ₹16.09 | -43.63% | +67.65% |
Operating margin of 23.12% compares with a Healthcare sector median of 24.64% across 8 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -5.99% | -5.56% |
Volume on the results session was 3.06× its 20-day average.
What to watch
- Whether sequential revenue improves from Rs 329.67 cr.
- Whether operating margin recovers from 23.12% after the 12.61 percentage-point sequential decline.
- Whether the tax rate moves below 27.83% while other income remains a limited 1.73% of pre-tax profit.